Passage Bio, Inc. (PASG)

Passage Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-84.44	-102.06	-136.13	-185.39	-112.23	-45.63
Depreciation & Amortization	3.55	3.72	3.68	1.54	0.8	0.13
Share-Based Compensation	9.73	10.92	18.95	32.69	14.58	1.45
Other Operating Activities	-3.59	9.16	-4.72	24.27	16.33	4.15
Operating Cash Flow	-74.75	-78.26	-118.21	-126.88	-80.52	-39.9
Capital Expenditures	-0.12	-0.15	-5.27	-25.64	-1.65	-1.19
Change in Investments	69.39	65.38	30.47	-20.17	-170.46	0
Other Investing Activities	-	-	-	-	-	-0.5
Investing Cash Flow	69.27	65.24	25.2	-45.81	-172.11	-1.69
Share Issuance / Repurchase	8.88	0.14	0.43	166.99	228.75	0.18
Debt Issued / Paid	0	0	-1.79	0	0	0
Other Financing Activities	-	-	-	-0.34	-	175.43
Financing Cash Flow	8.88	0.14	-1.35	166.66	228.75	175.6
Net Cash Flow	3.4	-12.89	-94.36	-6.04	-23.87	134.01
Free Cash Flow	-74.87	-78.41	-123.48	-152.52	-82.17	-41.09
Free Cash Flow Per Share	-1.33	-1.43	-2.27	-2.86	-2.13	-9.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).